Literature DB >> 34021843

Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis.

Vanita Noronha1, Vijay M Patil1, Gunjesh Kumar Singh1, Amit Joshi1, Nandini Menon1, Sarbani Ghosh Lashkar2, Vijayalakshmi Mathrudev1, Kavita Nawale Satam1, Kumar Prabhash3.   

Abstract

BACKGROUND: Acute oral mucositis has been infrequently studied in the patients with head and neck squamous cell carcinoma (HNSCC) receiving once-weekly cisplatin-based chemoradiotherapy (CRT). Hence, this analysis was conducted to explore the various aspects of the same.
RESULTS: The overall incidence of mucositis was 96.9% (n = 508) and of grade 3-5 mucositis was 61.3% (n = 321). The overall incidence of oral mucositis was similar in both the arms (CCRT and NCRT) (p value = 0.58) while grade 3-5 mucositis was more common in the NCRT arm (p value = 0.01). Out of all factors listed, the presence of nimotuzumab was the only significant risk factor for the development of grade 3 or more oral mucositis (p value = 0.01); (OR = 1.64, 95%CI 1.15-2.32). Delays in the treatment delivery were similar in both the arms.
CONCLUSION: Acute oral mucositis is a common occurrence in locally advanced-HNSCC patients receiving chemoradiotherapy. Nimotuzumab is a significant factor for development of grade 3 and above oral mucositis.

Entities:  

Keywords:  Acute oral mucositis; Chemoradiation; Head and neck cancer

Year:  2021        PMID: 34021843     DOI: 10.1186/s43046-021-00069-1

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  13 in total

1.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

2.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Authors:  Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.

Authors:  Vijay Maruti Patil; Vanita Noronha; Amit Joshi; Jaiprakash Agarwal; Sarbani Ghosh-Laskar; Ashwini Budrukkar; Vedang Murthy; Tejpal Gupta; Manoj Mahimkar; Shashikant Juvekar; Supreeta Arya; Abhishek Mahajan; Archi Agarwal; Nilendu Purandare; Venkatesh Rangarajan; Arun Balaji; Sameer Vasant Chaudhari; Shripad Banavali; Sadhana Kannan; Atanu Bhattacharjee; Anil K D'Cruz; Pankaj Chaturvedi; Prathamesh S Pai; Devendra Chaukar; Gouri Pantvaidya; Deepa Nair; Sudhir Nair; Anuja Deshmukh; Shivakumar Thiagarajan; Vijayalakshmi Mathrudev; Aparna Manjrekar; Sachin Dhumal; Kamesh Maske; Arti Sanjay Bhelekar; Kavita Nawale; Arun Chandrasekharan; Nikhil Pande; Alok Goel; Vikas Talreja; Vijai Simha; Sujay Srinivas; Rohit Swami; Dilip Harindran Vallathol; Hollis Dsouza; Sameer Shrirangwar; Siddharth Turkar; George Abraham; Aditi Harsh Thanky; Usha Patel; Manish Kumar Pandey; Kumar Prabhash
Journal:  Cancer       Date:  2019-05-31       Impact factor: 6.860

4.  Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.

Authors:  Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; David Adelstein; Jan B Vermorken
Journal:  Oral Oncol       Date:  2017-12-08       Impact factor: 5.337

5.  Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.

Authors:  Vanita Noronha; Amit Joshi; Vijay Maruti Patil; Jaiprakash Agarwal; Sarbani Ghosh-Laskar; Ashwini Budrukkar; Vedang Murthy; Tejpal Gupta; Anil K D'Cruz; Shripad Banavali; Prathamesh S Pai; Pankaj Chaturvedi; Devendra Chaukar; Nikhil Pande; Arun Chandrasekharan; Vikas Talreja; Dilip Harindran Vallathol; Vijayalakshmi Mathrudev; Aparna Manjrekar; Kamesh Maske; Arati Sanjay Bhelekar; Kavita Nawale; Sadhana Kannan; Vikram Gota; Atanu Bhattacharjee; Shubhada Kane; Shashikant L Juvekar; Kumar Prabhash
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

Review 6.  Radiation induced oral mucositis: a review of current literature on prevention and management.

Authors:  Supriya Mallick; Rony Benson; G K Rath
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-27       Impact factor: 2.503

7.  Spectrum of fungal infection in head and neck cancer patients on chemoradiotherapy.

Authors:  Gunjesh Kumar Singh; Malini R Capoor; Deepthi Nair; K T Bhowmik
Journal:  J Egypt Natl Canc Inst       Date:  2017-03-01

8.  Current trends in the management of oral mucositis related to cancer treatment.

Authors:  Biswa Mohan Biswal
Journal:  Malays J Med Sci       Date:  2008-07

9.  3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.

Authors:  Seth Helfenstein; Oliver Riesterer; Urs R Meier; Alexandros Papachristofilou; Benjamin Kasenda; Miklos Pless; Sacha I Rothschild
Journal:  Radiat Oncol       Date:  2019-02-11       Impact factor: 3.481

10.  The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity.

Authors:  Din-Li Tsan; Chien-Yu Lin; Chung-Jan Kang; Shiang-Fu Huang; Kang-Hsing Fan; Chun-Ta Liao; I-How Chen; Li-Yu Lee; Hung-Ming Wang; Joseph Tung-Chieh Chang
Journal:  Radiat Oncol       Date:  2012-12-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.